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Skeletal muscle has been identified as an endocrine organ that releases myokines with 
contraction. These myokines have been defined as cytokines and peptides that are produced, 
expressed, and released by muscle fibers that can have either an autocrine, paracrine, or 
endocrine action1. Interleukin-6 (IL-6) has been identified as a prototypic exercise myokine and 
can be measured in plasma after a single, acute bout of exercise2. IL-6, however, has 
implications in both the development and prevention of metabolic disease. The effect of exercise 
duration on IL-6 has been outlined in the literature3–5, but the effect of exercise intensity has yet 
to receive the same attention. In addition, racial disparities in the development of metabolic 
disease have been shown with African Americans having a significantly greater prevalence of 
CVD and type 2 diabetes than Caucasians in the United States6.    
PURPOSE: The purpose of the present study was to determine the effects of moderate and high 
intensity aerobic exercise training on basal, plasma IL-6 in overweight and obese African 
American individuals. 
METHODS: A randomized controlled trial was performed on overweight and obese (body mass 
index of 25-45 kg/m2), sedentary African American individuals (35-65 years) (n=24). 
 
 
Participants were randomly assigned to either a non-exercise control group or a moderate or high 
intensity aerobic exercise training group for 24 weeks. Supervised exercise was performed at a 
heart rate associated with 45-55% of VO2 max for the moderate intensity group or 70-80% of 
VO2 max for the high intensity group for a total exercise dose of 600 metabolic equivalents of 
task (MET-) minutes per week. Pre- and post-exercise intervention 12-hour fasted intravenous 
glucose tolerance tests (IVGTT) were performed. IVGTT samples were analyzed for insulin, 
glucose, lactate, and IL-6 using the Beckman Coulter clinical analyzer system. Bergman’s 
Minimal Model7 was used to assess insulin and glucose kinetics of the IVGTT. Additional blood 
samples were also drawn and sent to a clinical laboratory (LabCorp Inc., Burlington, NC) to be 
analyzed for a complete lipid and metabolic profile.  
RESULTS: In the control group, there were 11 participants, 6 participants in the moderate 
intensity exercise group, and 7 participants in the high intensity exercise group. No significant 
differences were found between the randomization groups for age, gender, weight, BMI, waist 
circumference, body fat percentage, glucose, insulin, and IL-6. Baseline BMI was significantly 
associated with baseline HOMA-IR (r=786, p<0.01) and baseline insulin (r=0.784, p<0.01). 
There was no significant change in IL-6 with the moderate or high intensity exercise group 
compared to the control group (p=0.8364). In addition, there was no significant change in SI 
(p=0.233), DI (p=0.422), or HOMA-IR (p=0.653). There was no significant correlation between 
relative fold change of IL-6 and SI (p=0.772), DI (p=0.545), or HOMA-IR (p=0.165).  
CONCLUSION: The present study did not find that moderate intensity aerobic exercise training 
nor high intensity aerobic exercise training decreased basal, plasma IL-6 in sedentary, obese and 
overweight African Americans. Insulin sensitivity was not improved in either exercise group 
when compared to the non-exercise control group. A broader scope on IL-6 is suggested for 
 
 
future studies and should include not only plasma but adipocyte IL-6 production as well as 
mRNA for IL-6. In addition, allowing enrollment of Caucasian individuals will allow for a direct 
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Chapter I: Introduction 
 
 In the past two decades, skeletal muscle has been found to be an endocrine organ that 
releases myokines. These myokines have been defined as cytokines and peptides that are 
produced, expressed, and released by muscle fibers that can have either an autocrine, paracrine, 
or endocrine action1. They play a particularly important role in crosstalk with various tissues, 
such as the liver, adipose tissue, brain, and bone3, and are largely secreted in response to muscle 
contraction8. Through mRNA sequencing, up to 250 myokines have been identified3, but 
interleukin-6 (IL-6) is one of the most extensively researched. Because myokines are secreted 
through skeletal muscle contraction, IL-6 has been suggested to play a role in the benefits of 
physical activity9.  
 The amount of IL-6 produced and released is dependent on both the intensity and 
duration of physical activity2, though studies have shown that duration is the biggest factor in 
regard to the magnitude of IL-6 released4,5. With prolonged exercise bouts, plasma IL-6 
increases of up to 100-fold of resting values can be consistently seen. Studies have also shown a 
positive correlation between exercise intensity and plasma IL-65,10, but attribute IL-6 increases to 
the increase in muscle mass used at higher intensities. Differences in IL-6 increases with exercise 
may be due to sampling methods. Many studies measure IL-6 concentrations in plasma, but there 
exists a high variance between blood sampling methods. Other studies measure IL-6 changes 
with mRNA instead and have seen similar, yet less pronounced increases with exercise11. 
Inconsistencies on the magnitude of plasma IL-6 increases with exercise have also been noted 
when trained athletes are compared to sedentary participants12. Overall, changes in IL-6 due to 
exercise are variable and depend highly on the population studied, the sampling method, and the 
nature of the exercise.  
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Decreased plasma IL-6 concentrations at rest and in response to exercise are now 
understood to be a normal training adaptation, with higher levels of physical activity reflecting 
lower resting plasma IL-613–15. Physical activity is also known to increase insulin sensitivity for 
both non-insulin resistant and insulin resistant populations. It is understood that physical activity 
plays an essential role in the treatment and prevention of insulin resistance. However, it is 
unknown if the change in insulin sensitivity with exercise is correlated to the change in basal IL-
6 or these two adaptations occur independently of each other. 
 IL-6 is a highly researched myokine, yet there still seems to be limited information 
looking at the effect exercise intensity has on plasma IL-6, especially in sedentary individuals. 
There also exists an inconsistency on the magnitude of changes in IL-6. The present study will 
lead to a better understanding of myokine changes in response to exercise. 
Hypothesis 
 Resting plasma IL-6 is lower in sedentary, overweight and obese African American 
individuals who complete a high intensity exercise program than a moderate intensity exercise 
program. In addition, decreases in IL-6 correlate to increases in insulin sensitivity. 
Purpose 
 The purpose of this study was to measure resting plasma IL-6 levels in response to 
exercise intensity in sedentary, overweight and obese African American individuals. 
Delimitations 
1. All individuals had a Body Mass Index (BMI) of 25.0 – 45.0 kg/m2. 
2. All individuals were sedentary. 




1. Exercise intensity was limited to moderate and vigorous, which limits the generalizability 
of the results to other exercise intensities. 
2. All exercise training was done on a treadmill, which limits the generalizability of the 
results to other modes of exercise training.  
3. The present study only used sedentary, overweight and obese African Americans, which 
limits the generalizability of these results to other BMI classifications and ethnicities.  
4. This study used only aerobic exercise, thus limiting the generalizability of the results to 
other forms of exercise.  
5. Only African American individuals were recruited, which did not allow for the direct 
comparison of intervention variables across different races.  
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Chapter II : Review of the Literature 
Introduction 
 The purpose of the current study was to examine differences of the myokine interleukin-6 
in plasma in response to different exercise intensities. The following literature review will 
discuss: 1) myokines and their functions in skeletal muscle, 2) interleukin-6 and its response to 
exercise, 3) insulin sensitivity changes with exercise and IL-6, and 4) racial disparities in 
exercise responses. 
 
Myokines in skeletal muscle 
 The secretory properties of skeletal muscle were discovered in the past two decades1, and 
thus myokine research is fairly new and the full scope of its functions and effects is still being 
determined. Myokines have been suggested to be classified as cytokines and peptides that have 
either an autocrine, paracrine, or endocrine action1. Through mRNA sequencing, almost 250 
genes for encoding myokines were discovered that are regulated with exercise3. They have also 
been found to be especially important in tissue cross talk, such as with the liver, adipose tissue, 
brain, and bone16. Tissue cross talk, or communication between different tissues with a 
subsequent change in whole body metabolic homeostasis, is particularly important between 
adipose tissue and skeletal muscle tissue. Adipose tissue releases adipokines which are secreted 
proteins that also act in an endocrine manner and facilitate this tissue-to-tissue cross talk that is 
connected to the delicate balance of metabolism17,18. Myokines in connection to metabolic 
disease and function are an important area of research as studies have shown myokines can have 
positive effects on glucose uptake19–23, glucose tolerance24, fat oxidation regulation24,25, and 
satellite cell proliferation26–28.  
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 Myokines are secreted with muscle contraction; thus it can be said that physical activity 
plays a large role in the expression of these myokines8. In response to exercise, there exist 
differences in myokine response rates. Some myokines are fast-responders meaning that their 
concentration is quickly changed after a brief bout of physical activity, but others are slow-
responders and require more long-term, consistent physical activity to show a change in 
concentration3. Myokines also show both beneficial and harmful effects on the body dependent 
on the amount released. For many, a low concentration will be beneficial, but both a lack and a 
high concentration can cause adverse effects29. By viewing skeletal muscle as a secretory organ 
and understanding that for some myokines their production and release is fully dependent on the 
contraction of skeletal muscle, it allows an insight into physical inactivity being linked even 
further with many chronic diseases and disorders, such as insulin resistance, type 2 diabetes, 
cardiovascular disease, and cancer16.  
 
Interleukin-6 and exercise 
 IL-6 is considered both a myokine and a cytokine29, and is one of the first extensively 
researched myokines30. It is considered to be a prototypic exercise myokine since it is one of the 
first myokines to start circulating after muscular contraction and is a fast responder to physical 
activity and can even be released after a single, acute bout of exercise. IL-6 levels can increase 
up to 100-fold after exercise2. The amount produced and released is dependent on both the 
intensity and duration of physical activity2. Studies have mapped out increases in IL-6 with 
varying exercise durations4, but as of yet the same has not been done for exercise intensities. 
Exercise intensity is harder to control than exercise duration, so many studies focus on detailing 
IL-6 increases with duration.  
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Physical activity activates transcription factors creating an increase in IL-6 that is then 
released from both skeletal muscle and adipose tissue29. Regulation of IL-6 is mainly done at the 
transcriptional level31. If released from skeletal muscle, the amount of IL-6 produced also 
depends on the glycogen supply of the muscle. Lower amounts of IL-6 are released when 
skeletal muscle has a higher glycogen content. Regular training and exercise increase the 
glycogen content of the muscle, so lower basal plasma levels of IL-6 are seen with regular 
physical activity. Many studies have noted that basal IL-6 is sensitive to regular physical 
activity14–16,32. When basal IL-6 was categorized by weekly physical activity minutes, those who 
performed 180 or more minutes were found to have the lowest basal concentration of IL-6. 
Those who performed 1-180 minutes had the second lowest basal IL-6, and those who did no 
exercise had the highest basal IL-6. A linear trend was found for decreases in basal IL-6 and 
increases in weekly exercise, so it is suggested that basal IL-6 is particularly sensitive to total 
amount of exercise14. Regular physical activity also increases the basal expression of IL-6 
receptors, so although circulating IL-6 is lower, the muscle becomes increasingly more sensitive 
to the myokine29. 
 Previously, elevated IL-6 concentrations were connected with increased creatine kinase 
levels and skeletal muscle damage from exercise33 making it unclear if damaged muscle caused 
the increased production of myokines or if it was the increased myokines causing the muscle 
damage. When skeletal muscles of rats were electrically stimulated for both concentric and 
eccentric contractions, mRNA levels of IL-6 were increased significantly in the stimulated 
muscle only with both types of contraction34. This helps indicate that the increased expression of 
IL-6 is through skeletal muscle locally producing the myokine as a response to damage in the 
muscle or connective tissue. Further, plasma IL-6 has been shown to be greater with eccentric 
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rather than concentric exercise although concentric exercise also increases plasma IL-633,35. With 
all exercise, however, an increase in skeletal muscle IL-6 is accompanied by an increase in 
plasma IL-6. Many studies have shown a correlation between plasma and skeletal muscle IL-6 
but few have shown the increase in plasma IL-6 to be the cause of increased skeletal muscle 
production of the myokine11,16,30,36–38. Steensberg et al.30 looked at arterial IL-6 concentrations 
compared to skeletal muscle IL-6 production and found that IL-6 in skeletal muscle was about 17 
times higher than in plasma. This shows that during muscular exercise, IL-6 has a high turnover 
rate in skeletal muscle, helping to explain the high variance seen between plasma and skeletal 
muscle IL-6. Further, it may be that IL-6 itself has a high clearance rate in general rather than 
specific to skeletal muscle tissue. When recombinant human IL-6 (rhIL-6) was injected in rats to 
measure biological activity, it was found that the peak concentration in plasma only accounted 
for half of the initially injected rhIL-631. Together, this shows that IL-6 clears quickly in 
circulation when both produced in skeletal muscle and when injected intravenously. Castell et 
al.31 also reported a half-life of 5-11 minutes for IL-6, and that IL-6 clearance occurs in a 
biphasic manner. The clearance of IL-6 from plasma occurs through two exponential 
components of which the initial component is rapid and the latter slow. The initial has an average 
of about 3 minutes, and the latter has an average of about 55 minutes. Morettini et al.39 
confirmed these findings through the use of a mathematical model and subsequent analysis of 
data sets from four experimental studies implementing exercise protocols with sampled plasma 
IL-6. A half-life of 13 minutes was found for IL-6 through this method. To the knowledge of the 




Insulin sensitivity with exercise and IL-6 
Physical activity is known to be beneficial for both non-insulin resistant and insulin resistant 
populations. One of the most important effects of physical activity is an increase in sensitivity to 
insulin. There are distinctive benefits from both a single acute bout of physical activity and 
general training adaptations. Benefits from an acute bout of physical activity last for at least 16 
hours post-activity and include improved glucose uptake in skeletal muscle and an increase in 
plasma membrane associated glucose transporter type 4 (GLUT4)40. General training adaptations 
include a continued increase in glucose uptake, an increase in GLUT4 translocation to the 
plasma membrane upon insulin stimulation, an increase in insulin responsiveness and sensitivity 
compared to untrained individuals, upregulation of muscle GLUT4 protein, increased enzyme 
capabilities, and muscle capillarization40. To maximize benefits, an emphasis on total work 
performed should be placed rather than exercise duration or intensity41.  
The role of IL-6 in insulin sensitivity and the induction of insulin resistance has largely been 
found to be inconclusive. IL-6 has been shown to be capable of impairing insulin signaling and 
action through its effects on gene transcription, reduction in expression of insulin receptor 
substrate 1 (IRS-1), GLUT4, peroxisome proliferator-activated receptor (PPARg), and decrease 
in insulin-stimulated glucose transport29,42–45. IL-6 has also been shown to increase GLUT4 
translocation46,47, increase glucose uptake42,47, increase glycogen synthesis46,48, increase fatty 
acid oxidization46–48, correlate to lower blood glucose and body weight49 and increase beta-cell 
proliferation in the pancreas50. Further, there exists more contradictory evidence whether IL-6 is 
beneficial or harmful and whether this occurs at high or at low concentrations of the myokine. 
Nieto-Vazquez et al.42 reported the dual action of IL-6 when exposing myotubes and mice to the 
myokine. With short-term exposure, glucose uptake and systemic insulin sensitivity were 
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increased. However, with chronic exposure, insulin resistance was seen through the impairment 
of GLUT4 translocation to the plasma membrane and defects in IRS-1. Bruunsgaard51 also notes 
the role of IL-6 as a “double edged sword”. Large but short-lived increases of IL-6, as seen with 
exercise, result in systemic benefits. Chronic, low-grade increases in IL-6 that are commonly 
seen with metabolic disease, however, will cause detrimental systemic effects. The rapid rate at 
which IL-6 is cleared from circulation also suggests that chronic increases in IL-6 are not 
desirable. In summary, further research is needed to determine the precise role of IL-6 in relation 
to insulin sensitivity. 
 
Racial disparities in exercise responses 
Compared to Caucasians, African American individuals are disproportionately affected 
by type 2 diabetes (T2D) and obesity. In the United States, African Americans have a prevalence 
rate of 14.7% compared to 7.5% for Caucasians for diabetes6. In addition, African American 
women have a higher prevalence of T2D compared to African American men. Although the 
exact reason behind this disparity in cardiometabolic disease is unknown, it has been posed that 
differences in insulin sensitivity are partly to blame. An increase in insulin resistance is a 
precursor to the development of T2D52–54 and physical activity is inversely related to both insulin 
resistance and the development of diabetes55–57. In the United States, the majority of African 
American individuals do not get the recommended amount of physical activity6,58. Supporting 
this, it is estimated that 30% of the racial disparity for T2D can be attributed to modifiable and 
non-modifiable risk factors, like physical inactivity, environment, and other lifestyle factors59. 
Because physical activity falls within these risk factors, it becomes increasingly important to 
understand the relationship between physical activity and its effects with this at-risk population. 
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Further, because IL-6 is still not entirely understood in its connection to insulin sensitivity, a 
deeper look into IL-6 and African American individuals needs to be done. 
When examining muscle fiber composition, differences between African American and 
Caucasian populations have been noted. Tanner et al. compared the muscle fiber types of African 
American and Caucasian women in muscle samples collected from the rectus abdominus 
muscle60. The African American individuals were found to have more type IIb and fewer type I 
fibers than the Caucasian individuals. This difference in muscle fiber types is notable because 
studies have shown that different muscle fibers release IL-6 in different magnitudes. Liang et 
al.61 found that IL-6 release is muscle fiber type specific, with IL-6 only being released from 
slow oxidative fibers but not fast glycolytic fibers with contraction. Another study found a 
similar result looking at gene transcription. IL-6 mRNA was higher in oxidative muscle fibers 
than glycolytic fibers62. From these results, it should follow that African American individuals 
have a lower production and release of IL-6 when compared to Caucasian individuals. However, 
Starzak et al. directly compared plasma IL-6 concentrations of African American and Caucasian 
individuals after a bout of exercise. Both groups performed the exercise for the same amount of 
time and at the same intensity. Cytokine concentrations were measured 3, 6, 9. 12, and 24 hours 
and 1, 2, and 3 weeks after the bout of exercise. They found that the African American 
individuals had significantly higher plasma IL-6 than the Caucasian individuals beginning at 6 
hours post-exercise and continuing to 2 weeks post-exercise63. These results are contradictory to 
what is predicted from muscle fiber type research. Thus, it is not clear if IL-6 is produced at a 





 Not only is IL-6 a relatively new research topic, but myokines in general are still not 
thoroughly understood in their pathways and peripheral effects on the body. There seem to be 
inconsistent results on the magnitude of IL-6 expression with physical activity. Concentrations of 
plasma IL-6 can vary significantly from mRNA expression of IL-6 in an individual64. 
Unfortunately, many papers do not specifically state the blood sampling method used for IL-6 
making it difficult to compare results between studies. Even when looking at only plasma 
concentrations of IL-6, levels can vary dependent on if the sample was taken from a venous 
catheter or a venous puncture 65,66, which reflects a lack of a standardized sampling method of 
IL-6. There is also little research that has looked at plasma IL-6 with solely exercise intensity 
and rather focuses on mapping the effects of exercise duration. Since exercise intensity is 
frequently associated with a shorter duration, the relationship between the myokine and intensity 
may be more pronounced and needs further research. Finally, there exists contradictory research 
on IL-6 production in African Americans. It is suggested that African American women have 
more type IIb and fewer type I muscle fibers when compared to their Caucasian counterparts. 
Type I and type IIa muscle fibers have been shown to produce more IL-6, yet African Americans 
have shown a significantly higher IL-6 plasma concentration than Caucasians after an identical 
bout of exercise. In all, a better understanding of IL-6 may help to in turn explain its roles in 




Chapter III: Methods 
The purpose of the present study was to measure the changes in basal, plasma IL-6 and 
insulin sensitivity in sedentary, overweight and obese African American individuals after 
completion of a moderate and high intensity aerobic exercise training program. To help test this, 
data from the High Intensity exercise to Promote Accelerated improvements in Cardiorespiratory 
fitness (HI-PACE) study database has been used for the present study. The methodology of HI-
PACE was approved by the East Carolina Institutional Review Board, and all participants signed 
a written informed consent prior to enrollment. Sedentary, overweight and obese African 
American participants were randomized to three different groups (two exercise and one non-
exercise), performed an IVGTT pre-training and post-training, and resulting plasma samples 
were analyzed. This section provides a detailed summary of the study design, subjects, the 
exercise training protocol, IVGTT and sample analysis, and statistical analyses used to test the 
present study’s hypothesis. 
 
Study design 
 Two exercise intensities and a non-exercise control were examined: (1) control, (2) 
moderate intensity (45-55% VO2 max), and (3) high intensity (70-80% VO2 max). The rationale 
for examining these three groups was to provide a comparison of potential exercise effects in 
sedentary African American individuals. Participants were screened for exclusion criteria. A 
pretraining IVGTT was performed. Subjects then underwent 24 weeks of 3-4 days/week of 
supervised exercise training. A posttraining IVGTT was performed. Fasting baseline samples 





 Recruitment of participants was done through e-mail, online advertisement, and flyer 
distribution. A sample size of 60 was used for total participant recruitment, but only those with a 
complete IVGTT were included in the present study. The main inclusion criteria for the study 
was age, sex, BMI, activity level, ethnicity, and informed consent. Individuals must be 35-65 
years old. Both men and women were included but must have a BMI of 25.0-45.0 kg/m2. 
Individuals must have been sedentary and not participating in exercise training at the time of 
enrollment (<20 minutes and £2 days per week for the past 3 months). Individuals must have 
self-identified as African American. Finally, individuals must show willingness and capability to 
provide their written consent and to understand the exclusion criteria. Individuals were excluded 
if they were either type 1 or type 2 diabetic or had a fasting plasma glucose of ³126 mg/dL. No 
individuals could have cardiovascular disease or disorders including diagnosed congestive heart 
failure, serious arrhythmias, peripheral vascular disease with intermittent claudication, previous 
stroke, or myocardial infarction. Resting blood pressure could not include an excessively high 
resting systolic (>180 mmHg) or diastolic (>100 mmHg) blood pressure. Individuals that were 
on blood pressure medication at the time of recruitment were however permitted to enroll. Total 
cholesterol could not have been ³240 mg/dL, low-density lipoprotein cholesterol ³160 mg/dL, or 
triglycerides ³300 mg/dL. Other exclusionary medical conditions included chronic or 
reoccurring neuromuscular, respiratory, gastrointestinal, neurological, HIV, or psychiatric 
conditions, musculoskeletal conditions affecting exercise, current treatment for medical illness or 
hospitalization from mental illness from previous 5 years, autoimmune or collagen vascular 
diseases, and other medical conditions that were considered life-threatening or that can be 
provoked from exercise training. Finally, other exclusion criteria include pregnancy or plans to 
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become pregnant, current engagement or plans to engage in a weight loss or dieting program, 
previous bariatric surgery or weight loss medications, and plans to leave Pitt County in North 
Carolina for more than 2 weeks in the 6 months following recruitment. Participants were 
screened by study staff for inclusion and exclusion criteria via phone interview. Next, the 
participants attended a screening session to review study design and associated benefits and risks 
of participating in the study. Finally, baseline measurements and values were recorded, which 
included a fasted blood draw that was sent to a clinical laboratory for analyses. Medical history 
and screening measurements were reviewed by study staff. 
 
Anthropometry and body composition 
 After enrollment, baseline measurements were recorded including weight, height, body 
mass index (BMI), waist circumference (WC), and a dual energy x-ray absorptiometry (DXA) 
scan. A Digi Tol calibrated scale (Mettler Toledo, Columbus, OH) was used to record body 
weight in the fasted state. Height was recorded using a stadiometer. BMI was calculated from 
these measurements in kg/m2. WC was measured using a tape measure at the natural waist. 
DEXA (GE Lunar Prodigy Advance, Fairfield, CT, USA) was used to measure body 
composition (fat mass and fat-free mass).  
 
Exercise training 
 Upon completion of all baseline visits and approval received by the study physician, 
participants were randomized to the non-exercise control, moderate intensity, or high intensity 
group. All exercise sessions were supervised by study staff and performed on a treadmill. 
Participants randomized to the moderate-intensity exercise group performed exercise at a target 
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heart rate associated with 45-55% of their VO2 max. Participants randomized to the high-
intensity exercise group performed exercise at a target heart rate associated with 70-80% of their 
VO2 max. The heart rate range was determined for each participant from a maximal exercise test 
at baseline and mid-intervention. A total of 600 MET-minutes per week was performed by both 
exercise groups, which is consistent with current public health guidelines67. Because all 
participants were sedentary at the start of the study, a ramp protocol was used to build up to 600-
MET minutes per week. Individuals started at 50-MET minutes per week and increased by an 
additional 50-MET minutes per week until the exercise volume reached 600-MET minutes (week 
9). Participants were instructed to do a 5-minute warm-up prior to each exercise session and a 5-
minute cool-down at the end of each session. Heart rate was continuously monitored and 
recorded every 5 minutes during exercise to ensure maintenance of the target exercise intensity 
through the use of Zephyr Bioharness 3 Monitors (Annapolis, MD). 
 
IVGTT and insulin sensitivity 
 Participants completed an intravenous glucose tolerance test (IVGTT) prior to beginning 
exercise training and once more after completing training. The IVGTT was done 18-24 hours 
following the last exercise session for the exercise groups. The procedure used for the IVGTT is 
as described by Bergman et al.7. Subjects reported to the laboratory in the morning after a 12-
hour fast and completed a blood draw at the East Carolina Heart Institute. Three baseline 
samples were collected in addition to vials of archive plasma, serum, and red blood cells. Then, 
an intravenous injection of glucose (1.7 mmol/kg) was administered at time 0 and insulin (150 
pmol/kg) was administered at minute 20. Including the baseline samples, a total of 31 samples 
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were collected between -15 and 180 minutes. Blood samples were then centrifuged and stored at 
-80° until sample analysis was performed.  
 
Blood analysis  
 IVGTT samples were analyzed using a high sensitivity chemiluminescent immune assay 
for insulin and IL-6 using the Beckman Coulter Access II clinical analyzer. Samples were 
analyzed for lactate and for glucose using a hexokinase reaction on the Beckman Coulter 
DxC600 clinical chemistry analyzer (Beckman Coulter AU5800; Brea, CA). Bergman’s Minimal 
Model7 was be used to assess insulin and glucose kinetics of the IVGTT. The minimal model 
provides estimates of insulin secretion (acute insulin response to glucose, AIRG), insulin 
sensitivity (SI), and disposition index (DI). The SI is a measure that includes both the effect of 
insulin on glucose disappearance and reducing hepatic glucose production. The DI is a measure 
of pancreatic beta-cell function. HOMA-IR was calculated from baseline values and used as a 
measure of insulin resistance. 
 
Statistical analysis 
 A repeated measures ANOVA was used to compare participants pre- and post-training, as 
well as between different randomization groups. To measure the change in IL-6, an ANOVA was 
performed with an alpha level of £0.05 for all statistical analyses. A one-way ANOVA was used 
to compare baseline values to ensure no significant differences exist between groups initially. To 
analyze the correlation between baseline variables and variable fold-change, a Spearman 
correlation was done. Change scores were calculated to measure change in IL-6 across other 
baseline variables.  
 
 17 
Chapter IV: Results 
The baseline characteristics for each treatment group are reported in Table 1. In the 
control group, there were 11 participants. In the moderate intensity exercise group, there were 6 
participants. In the high intensity exercise group, there were 7 participants. No significant 
differences were found between randomization groups for age, gender, weight, BMI, waist 
circumference (WC), body fat percentage, glucose, insulin, and IL-6 (p>0.05).  Baseline BMI 
was significantly associated with baseline HOMA-IR (r=0.786, p<0.001) (Figure 7) and baseline 
insulin (r=0.784, p<0.001) (Figure 8). Table 2 reports relative fold changes and standard error of 
the mean (SEM) of intervention statistics for each treatment group. 
There was no significant difference in IL-6 with exercise (p=0.1211) (Figure 1). There 
was no significant change in IL-6 with the moderate intensity or the high intensity group when 
compared to the control group (p=0.8364) (Figure 2). Relative fold changes for IL-6 were 1.04, 
1.43, and 1.03 for the control, moderate intensity, and high intensity group, respectively (Figure 
3).  In addition, there was no significant change in SI (p=0.233), DI (p=0.422), or HOMA-IR 
(p=0.653). Correlation analyses showed no significant association between IL-6 and SI (r=-
0.062, p=0.772) (Figure 4), DI (r=-0.130,p=0.545) (Figure 5), or HOMA-IR (r=-0.293, p=0.165) 




Chapter V: Discussion 
 The primary finding of the present study was that neither moderate nor high intensity 
exercise training reduced interleukin-6 in overweight and obese African American individuals. 
Further, no significant changes in insulin sensitivity were found. These results are in contrast to 
previous studies in the literature, but it is important to note that other benefits from aerobic 
exercise training still exist 68,69. This is the first study to the author’s knowledge that has 
evaluated the effect of differing exercise intensities on IL-6 levels through an exercise training 
program, specifically in overweight and obese, sedentary African American individuals. 
 The purpose of this study was to examine the effect of moderate and high intensity 
training on basal, plasma IL-6 of overweight and obese, sedentary African American individuals, 
as well as further investigate the relationship between IL-6 and insulin sensitivity. Although 
other studies have suggested a relationship between exercise intensity and IL-6 as well as 
improvements in insulin sensitivity with exercise training, the present study did not observe any 
significant changes in basal, plasma IL-6 or any improvements in insulin sensitivity following 24 
weeks of supervised aerobic exercise training. The present study found mean values of 
4.15±3.74, 3.10±0.74, and 5.01±4.8 pg/mL for plasma IL-6 in our control, moderate, and high 
intensity groups, respectively. Although plasma IL-6 varies across populations and is influenced 
by geography, etiology, and health status, a reference range of 0.015-10.01 pg/mL was reported 
by Ridker et al.70. While our plasma IL-6 values fall within this reference range, our mean values 
differ largely from other studies. In populations of similar age, sex, and BMI, mean plasma IL-6 
values of 1.8971, 1.6672, and 2.873 pg/mL have been measured. Gudmundsson et al.65 reported 
that concentrations of plasma IL-6 may increase when sampled through an indwelling venous 
catheter. Although the use of an indwelling venous catheter for experimental models such as an 
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IVGTT is the accepted choice, their results indicated that the frequent sampling may result in a 
cytokine cascade that results in increased IL-6 production due to the continuous disruption of the 
endothelial layer. Endothelin is produced by epithelial cells, has been shown to be an effective 
stimulator of IL-674, and is released into circulation with indwelling venous catheters. It is 
suggested that the higher IL-6 concentration seen with this sampling method is reflective of local 
production rather than the circulating concentration. This data taken into account with the 
disproportionate difference of IL-6 production in skeletal muscle and IL-6 circulation in plasma 
helps to provide a potential explanation on the present study’s results. In addition, the authors of 
the present study recognize that an IVGTT is not a stress-free environment for study participants. 
This is important to note due to the relationship between stress and IL-6. In previous sections, it 
has been noted that IL-6 acts as an indicator of systemic stress, such as with type 2 diabetes, 
obesity, and inflammation. Further, IL-6 is suggested to act as an indicator of all stress signals 
and be a fundamental component of the organism’s stress sensor75. Thus, it is plausible that 
increased plasma IL-6 concentrations at the time of the IVGTT could be indicative of an acute 
stress response. To mitigate this problem, we suggest that plasma IL-6, mRNA for IL-6 in 
skeletal muscle, receptors for IL-6 in skeletal muscle, and adipocyte IL-6 be studied. Although 
skeletal muscle accounts for a large proportion of IL-6 production, other tissues should not be 
ignored. Adipose tissue has been shown to release significant amounts of IL-6 and there exists a 
strong, positive correlation between arterial IL-6 concentration and BMI66. In the present study, 
there was no significant change in BMI in either the moderate intensity or the high intensity 
exercise group when compared to the non-exercise control group. Due to this, it is also plausible 
that there needs to be a significant amount of weight loss to see a significant decrease in IL-6. In 
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addition, further research could allow enrollment for both Caucasian and African American 
individuals to allow a direct comparison of intervention variables between races.  
 Despite the results, the present study had many strengths. All exercise training was 
supervised, and participants were continuously monitored to ensure appropriate exercise 
intensity. This allowed for a high adherence rate for both exercise intensity groups. In addition, a 
particular strength of this study was the equivalent total exercise volume performed by the 
moderate and high intensity group, which allowed for mediation of the effects of exercise 
duration on IL-6. A weakness of the study was the majority of participants were female. Also, 
these results will not be able to be generalized to a diabetic population. 
 In conclusion, the present study did not find that moderate exercise intensity training nor 
high intensity exercise training decreased basal, plasma IL-6. In addition, insulin sensitivity was 
not improved in either group. We suggest a broader look at IL-6 for future studies as well as a 
larger sample size. Studying IL-6 with a multi-tissue approach would allow for a better 
understanding of IL-6 at a systemic level and could potentially provide more insight into the role 
IL-6 has in muscle-adipose tissue crosstalk. In addition, we suggest dietary interventions be 





Tables and Figures 
 
Table 1: Baseline Participant Characteristics 
 




Age (yrs.) 49 ± 6 51 ± 8 46 ± 9 
Sex (%) 1.73 ± 0.5 1.67 ± 0.5 1.71 ± 0.5 
Weight (kg) 92.01 ± 17.9 95.78 ± 12.8 99.87 ± 19 
BMI (kg/m2) 32.5 ± 6.1 32.73 ± 2.9 35.9 ± 5.5 
WC (cm) 94.05 ± 12.6 95.44 ± 10.5 102.73 ± 13.9 
Fat Mass (kg) 39.55 ± 8.7 40.1 ± 8.1 43.03 ± 6.7 
VO2 (ml/kg/min) 21.76 ± 5.3 20.88 ± 5.4 18.53 ± 4.3 
Glucose (mg/dL) 85.77 ± 8.2 92.76 ± 4.5 88.61 ± 4.7 
Insulin (uU/mL) 8.92 ± 7.3 8.76 ± 3.4 12.43 ± 9.5 
SI [min−1/(μU/mL)] 
 
4.95 ± 4.9 3.06 ± 1.1 2.25 ± 1.6 
DI  6420 ± 10291 2067 ± 1441 1943 ± 1432 
Lactate (mMol) 1.61 ± 0.2 1.67 ± 0.2 1.66 ± 0.3 
HOMA-IR 1.96 ± 1.7 2.02 ± 0.8 2.71 ± 2.0 






Table 2: Relative (post-training/pre-training) Changes in Intervention Statistics; Mean ± SEM 
 
Variable Control               
(n=11) 
Mod Intensity   
(n=6) 
High Intensity      
(n=7) 
 △ Weight (kg) 1.00 ± 0.01 1.02 ± 0.01 0.99 ± 0.02 
△ BMI (kg/m2) 1.00 ± 0.01 1.02 ± 0.01 0.99 ± 0.02 
△ WC (cm) 1.00 ± 0.01 1.04 ± 0.02 1.00 ± 0.01 
△ Fat Mass (kg) 0.99 ± 0.01 1.00 ± 0.03 0.97 ± 0.02 
△ VO2 (ml/kg/min) 0.99 ± 0.04 1.05 ± 0.06 1.18 ± 0.04 
△ Glucose (mg/dL) 1.05 ± 0.03 1.00 ± 0.06 0.99 ± 0.04 
△ Insulin (mL) 1.05 ± 0.11 0.76 ± 0.10 1.04 ± 0.09 
△ SI 1.06 ± 0.24 1.33 ± 0.39 2.80 ± 1.69 
△ DI 1.25 ± 0.31 1.34 ± 0.54 2.66 ± 1.66 
△ Lactate 1.05 ± 0.03 0.92 ± 0.05 1.07 ± 0.07 
△ HOMA-IR 1.11 ± 0.12 0.77 ± 0.11 1.04 ± 0.10 
△ IL-6 1.04 ± 0.11 1.43 ± 0.28 1.03 ± 0.08 
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Figure 2. Mean basal plasma IL-6 before and after 24 weeks of aerobic exercise training 
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